LaNova Medicines

There were fireworks ahead of the 4th of July festivities over the pharma sector as analysts weighed in on the rumors that a multi-billion dollar deal is in the offing between AstraZeneca and Summit T

Bristol Myers Squibb is following Merck & Co. and Pfizer by buying into the bispecific PD-L1xVEGF-targeting mechanism for cancer, announcing on June 2 that it will pay $1.5bn up front to BioNTech

Results from a Phase III study in China of Akeso and Summit Therapeutics’ ivonescimab in non-small cell lung cancer (NSCLC) are an encouraging sign for the PD-1/VEGF-targeting bispecific antibody’s pi

Metabolic disease alliances have picked up as companies try to find a spot in the growing obesity market, and earlier this decade the COVID-19 pandemic drove a short-lived uptick in infectious disea